List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    SBC: Siteone Therapeutics, Inc.            Topic: 105

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic painsuch as pain associated with chemotherapy induced peripheral neuropathythat targets an isoform of the voltage gated sodium ion channelNaVVoltage gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in the periphe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Acoustic Enhanced Cell Culture

    SBC: RESODYN CORPORATION            Topic: 400

    This Small Business Innovation Research Phase I project will develop a prototype and then evaluate a novel device that utilizes low frequency sound energy to enhance cell culture productivityThe acoustic micromixing generated by the proposed device is compatible with cells and possesses the capability to substantially enhance the culture efficiency of cells cultured in typical culture vesselsThis ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of NaV1.7 Inhibitors for the Treatment of Chronic Cough

    SBC: Siteone Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARYThe objective of our program is to develop a safe and effective therapeutic for chronic coughChronic coughor cough that persists for more than eight weeksis a condition that is often associated with diseases such as chronic obstructive pulmonary disorderCOPDasthmaidiopathic pulmonary fibrosisbronchiectasis or gastroesophageal reflux diseaseGERDIn other casesthe etiology is unknownCh ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Topical selective T-type blockers for the treatment of pruritus

    SBC: Dermaxon LLC            Topic: NIAMS

    Project SummaryAbstractPruritusalso called itchis the most frequent dermatological symptom in the US with up toof Americans being affectedPruritic stimuli are detected by a subset of nociceptive neuronspruriceptorswhich fire action potential in response to peripheral activation by THor THmolecules induced by chronic inflammatory skin diseases such as ichthyosisprurigo nodularisand hidradenitis sup ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Project isoPTE: isothermic post-traumatic epilepsy miRNA biomarker detection

    SBC: FYR DIAGNOSTICS, LLC            Topic: 999

    Project Summary Acquired epilepsy results from acute brain injurysuch as traumatic brain injuryTBIAcquired epilepsy is a major public health issue with inadequate treatment and diagnostic optionsThere are no biomarkers that assist in the prediction or diagnosis of acquired epilepsyProject isoPTE will use two animal models of epilepsy to determine whether plasma microRNAmiRNAbiomarkers can predict ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder

    SBC: Montana Molecular LLC            Topic: NIDA

    ! Project Summary Millions of Americans today have an opioid use disorderOUDMillions more misuse opioidsand the crisis continues to growThe goal of this proposal is to speed the discovery of non addictive analgesics by providing drug discovery teams with simplermore robustmore quantitativeassays for agonist biasDriven by the urgency of the problem we are seeking Fast Track support to create new as ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Developing EXP-1801 as an imaging agent to quantify pain and analgesia

    SBC: Expesicor Inc            Topic: NINDS

    Summary Abstract There are currently no tools available that can objectively measure painHistoricallypain in humans has been measured using subjective ratings to determine presence and severityIn animal modelspain is measured by semi quantitative assays that rely on the observation of pain behaviorsThough usefulthe inherently subjective nature of these measures has hampered both research and treat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Modeling drug-refractory epilepsy with the KaL method

    SBC: Expesicor Inc            Topic: NINDS

    Epilepsy is a common neurological disorder that is characterized by recurrentspontaneousseizuresEpilepsy is a major public health issue with inadequate treatment optionsOvermillion people worldwide have epilepsyThis is more than cerebral palsymultiple sclerosisandParkinson s disease combinedAlthough more than two dozen antiseizure drugsASDsexistapproximately one third of patientsovermillionsuffer ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis

    SBC: INIMMUNE CORP            Topic: NIAID

    The long term goal of this proposal is the development of an intranasal stand alone TLRagonist to treat allergic rhinitisUnlike antigen specific therapythis allergen independent approach will be broadly applicable to a vast array of allergens patients are exposed toSuch treatment would provide relief within hours of administrationproviding short term symptom controland has the potential to deliver ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. I-Corps Proposal for Commercialization of Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease

    SBC: Montana Molecular LLC            Topic: NINDS

    SUMMARY ABSTRACT The goal of our predicate SBIR Phase I award is to develop genetically encoded fluorescent assays to detect cell stress in models of neurodegenerationTypically this degeneration is studied by counting dead cellsin animal or cellular models of the diseasewhich is an insensitive measurement of chronicslowcellular stressOur goal is to create genetically encodedfluorescent biosensors ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government